Patterns of NSAIDs Use and Their Association with Other Analgesic Use in CKD.

BACKGROUND AND OBJECTIVES Avoiding nonsteroidal anti-inflammatory drugs is important for safe CKD care. This study examined nonsteroidal anti-inflammatory drug use patterns and their association with other analgesic use in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The Chronic Renal Insufficiency Cohort Study is an observational cohort study that enrolled 3939 adults ages 21-74 years old with CKD between 2003 and 2008 using age-based eGFR inclusion criteria. Annual visits between June of 2003 and December of 2011 were organized into 15,917 visit-pairs (with an antecedent and subsequent visit) for 3872 participants with medication information. Demographics, kidney function, and clinical factors were ascertained along with report of nonsteroidal anti-inflammatory drug or other analgesic use in the prior 30 days. RESULTS In our study, 24% of participants reported nonsteroidal anti-inflammatory drug use at baseline or at least one follow-up study visit. Having a 10 ml/min per 1.73 m2 higher eGFR level at an antecedent visit was associated with higher odds of starting nonsteroidal anti-inflammatory drugs at a subsequent visit (odds ratio, 1.44; 95% confidence interval, 1.34 to 1.56). Seeing a nephrologist at the antecedent visit was associated with lower odds of starting or staying on nonsteroidal anti-inflammatory drugs at a subsequent visit (odds ratio, 0.70; 95% confidence interval, 0.56 to 0.87 and odds ratio, 0.61; 95% confidence interval, 0.46 to 0.81, respectively). Starting and stopping nonsteroidal anti-inflammatory drugs were both associated with higher odds of increasing the number of other analgesics (odds ratio, 1.52; 95% confidence interval, 1.25 to 1.85 and odds ratio, 1.78; 95% confidence interval, 1.39 to 2.28, respectively) and higher odds of increasing the number of opioid analgesics specifically (odds ratio, 1.92; 95% confidence interval, 1.48 to 2.48 and odds ratio, 1.46; 95% confidence interval, 1.04 to 2.03, respectively). CONCLUSIONS Nonsteroidal anti-inflammatory drug use is common among patients with CKD but less so among those with worse kidney function or those who see a nephrologist. Initiation or discontinuation of nonsteroidal anti-inflammatory drugs is often associated with supplementation with or replacement by, respectively, other analgesics, including opioids, which introduces possible drug-related problems when taking these alternative analgesics.

[1]  J. Lewis,et al.  Opioid Use in Hemodialysis Patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. Zhan,et al.  Chronic pain and analgesic use in CKD: implications for patient safety. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[3]  M. Yaqoob,et al.  Evaluating ethnic differences in the prescription of NSAIDs for chronic kidney disease: a cross-sectional survey of patients in general practice. , 2014, The British journal of general practice : the journal of the Royal College of General Practitioners.

[4]  Arsh K Jain,et al.  Dosing errors in prescribed antibiotics for older persons with CKD: a retrospective time series analysis. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  M. Pruijm,et al.  Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study , 2013, Annals of the rheumatic diseases.

[6]  Nilay D Shah,et al.  Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000–2010 , 2013, Medical care.

[7]  U. Kadam,et al.  Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. , 2013, Family practice.

[8]  T. MacDonald,et al.  Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function , 2013, Kidney international.

[9]  M. Zhan,et al.  Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal Anti-Inflammatory Drug Prescriptions in Chronic Kidney Disease , 2012, American Journal of Nephrology.

[10]  L. Køber,et al.  Use of nonsteroidal anti‐inflammatory drugs prior to chronic renal replacement therapy initiation: a nationwide study , 2012, Pharmacoepidemiology and drug safety.

[11]  Ian J. Brown,et al.  A comparison of self-reported analgesic use and detection of urinary ibuprofen and acetaminophen metabolites by means of metabonomics: the INTERMAP Study. , 2012, American journal of epidemiology.

[12]  N. Powe,et al.  Nonsteroidal Anti-Inflammatory Drug Use Among Persons With Chronic Kidney Disease in the United States , 2011, The Annals of Family Medicine.

[13]  T. Gill,et al.  Cause for concern in the use of non-steroidal anti-inflammatory medications in the community -a population-based study , 2011, BMC family practice.

[14]  Chun-Yuh Yang,et al.  Analgesic use and the risk for progression of chronic kidney disease , 2010, Pharmacoepidemiology and drug safety.

[15]  P. Pham,et al.  Pain prevalence in patients with chronic kidney disease. , 2010, Clinical nephrology.

[16]  A. Go,et al.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[17]  S. Waikar,et al.  Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. , 2008, The American journal of medicine.

[18]  M. Tonelli,et al.  NSAID use and progression of chronic kidney disease. , 2007, The American journal of medicine.

[19]  G. Molenberghs,et al.  Models for Discrete Longitudinal Data , 2005 .

[20]  Katrin Uhlig,et al.  Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  B. Rosner,et al.  Lifetime nonnarcotic analgesic use and decline in renal function in women. , 2004, Archives of internal medicine.

[22]  A. Go,et al.  The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. , 2003, Journal of the American Society of Nephrology : JASN.

[23]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  L. Strand,et al.  Documenting the Clinical Pharmacist's Activities: Back to Basics , 1988, Drug intelligence & clinical pharmacy.

[26]  H. Pogglitsch,et al.  [Drug dosage in renal insufficiency]. , 1976, Wiener medizinische Wochenschrift.

[27]  M. Brookhart,et al.  Opioid use in the US hemodialysis population. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[29]  G. Wolf,et al.  Leptin and renal disease. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  M Wolfson,et al.  Drug prescribing in renal failure: dosing guidelines for adults. , 1983, American journal of kidney diseases : the official journal of the National Kidney Foundation.